Literature DB >> 10361663

Intrathecal morphine. Double-blind evaluation of optimal dosage for analgesia after major lumbar spinal surgery.

A P Boezaart1, J A Eksteen, G V Spuy, P Rossouw, M Knipe.   

Abstract

STUDY
DESIGN: A prospective, randomized, double-blind study.
OBJECTIVES: To evaluate the efficacy and safety of three different dosages of intrathecal morphine sulfate for postoperative analgesia after lumbar spinal fusion. SUMMARY OF BACKGROUND DATA: Analgesia and respiratory depression after intrathecal morphine sulfate injection are dose related. The optimal dose to use for major spinal surgery is not known.
METHODS: Sixty patients undergoing posterolateral lumbar fusion with or without decompression were divided randomly into 3 groups of 20 patients each. Anesthesia, monitoring, and surgery were similar for all patients. Just before closing of the wound, morphine sulfate was injected into the dural sack under direct visualization. Patients in groups 1-3 received 0.2 mg, 0.3 mg, and 0.4 mg morphine, respectively. Routine analgesia, consisting of diclofenac, was prescribed to use if necessary. Measurements were made and compared between the groups at zero hours (on admission to the Intensive Care Unit), 6 hours, 12 hours, 18 hours, and 24 hours after surgery.
RESULTS: At zero hours and at 12 hours after surgery, pain levels were similar in groups 2 and 3, but were significantly higher in group 1 (P < 0.05). The respiratory rate was significantly lower in group 3 than in the other two groups (P < 0.05), and the arterial CO2 tension (PaCO2) was consistently higher in group 3. PaCO2 decreased in all three groups over the first 24 hours. Pruritus and nausea did not differ among the three groups.
CONCLUSIONS: For adult patients undergoing posterolateral lumbar fusion, 0.3 mg (0.004 mg/kg) is probably the optimal dose of intrathecal morphine to manage pain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10361663     DOI: 10.1097/00007632-199906010-00013

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  7 in total

Review 1.  Neuraxial morphine and respiratory depression: finding the right balance.

Authors:  Pervez Sultan; Maria Cristina Gutierrez; Brendan Carvalho
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

Review 2.  Analgesic therapy for major spine surgery.

Authors:  Varun Puvanesarajah; Jason A Liauw; Sheng-fu Lo; Ioan A Lina; Timothy F Witham; Allan Gottschalk
Journal:  Neurosurg Rev       Date:  2015-02-14       Impact factor: 3.042

3.  Complications associated with intrathecal morphine in spine surgery: a retrospective study.

Authors:  Arif Pendi; Yu-Po Lee; Saif Al-Deen B Farhan; Frank L Acosta; S Samuel Bederman; Ronald Sahyouni; Elias R Gerrick; Nitin N Bhatia
Journal:  J Spine Surg       Date:  2018-06

4.  Is a single low dose of intrathecal morphine a useful adjunct to patient-controlled analgesia for postoperative pain control following lumbar spine surgery? A preliminary report.

Authors:  David Yen; Kim Turner; David Mark
Journal:  Pain Res Manag       Date:  2015 May-Jun       Impact factor: 3.037

5.  Comparative Effects of Buprenorphine and Dexmedetomidine as Adjuvants to Bupivacaine Spinal Anaesthesia in Elderly Male Patients Undergoing Transurethral Resection of Prostrate: A Randomized Prospective Study.

Authors:  Navdeep Kaur; Umesh Goneppanavar; Ramkumar Venkateswaran; Sadasivan Shankar Iyer
Journal:  Anesth Essays Res       Date:  2017 Oct-Dec

6.  Immediate postoperative pain level from lumbar arthrodesis following epidural infiltration of morphine sulfate.

Authors:  Carlos Alexandre Botelho do Amaral; Tertuliano Vieira; Edgar Taira Nakagawa; Eduardo Aires Losch; Pedro José Labronici
Journal:  Rev Bras Ortop       Date:  2015-02-19

7.  Pathway for enhanced recovery after spinal surgery-a systematic review of evidence for use of individual components.

Authors:  Ana Licina; Andrew Silvers; Harry Laughlin; Jeremy Russell; Crispin Wan
Journal:  BMC Anesthesiol       Date:  2021-03-10       Impact factor: 2.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.